

Số/No.: 319/IMP

Tp. Cao Lãnh, ngày 10 tháng 08 năm 2022
Cao Lanh City, day 10 month 08 year 2022

CÔNG BỐ THÔNG TIN
TRÊN CỔNG THÔNG TIN ĐIỆN TỬ
CỦA ỦY BAN CHỨNG KHOÁN NHÀ
NƯỚC VÀ SGDCK TP.HCM

DISCLOSURE OF INFORMATION ON THE
STATE SECURITIES COMMISSION'S
PORTAL AND HOCHIMINH STOCK
EXCHANGE'S PORTAL

Kính gửi/ To: - Ủy ban Chứng khoán Nhà nước/ *The State Securities Commission*
- Sở Giao dịch chứng khoán TP.HCM/ *Hochiminh Stock Exchange*

- Tên tổ chức / *Organization name*: Công ty Cổ phần Dược phẩm Imexpharm/
Imexpharm Corporation
- Mã chứng khoán/ *Securities Symbol*: IMP
- Địa chỉ trụ sở chính/ *Address*: Số 04, Đường 30/04, Tp. Cao Lãnh, tỉnh Đồng Tháp/
No. 04, 30/04 Street, Ward 1, Cao Lanh City, Dong Thap Province.
 - Điện thoại/ *Telephone*: (84.277) 3851941
 - Fax: (84.277) 3853106
- Người thực hiện công bố thông tin/ *Submitted by*: Ông Nguyễn Quốc Định/
Mr. Nguyen Quoc Dinh

Chức vụ/ *Position*: Chủ tịch Hội đồng quản trị / *Chairman*

Loại thông tin công bố: ☒ định kỳ ☐ bất thường ☐ 24h ☐ theo yêu cầu
Information disclosure type: ☒ Periodic ☐ Irregular ☐ 24 hours ☐ On demand

Nội dung thông tin công bố (*)/ *Content of Information disclosure (*)*:

Báo cáo tài chính giữa niên độ năm 2022 đã được soát xét bản tiếng Anh/ *Interim financial statements for the six-month period ended 30 June 2022.*

Tôi cam kết các thông tin công bố trên đây là đúng sự thật và hoàn toàn chịu trách nhiệm trước pháp luật về nội dung các thông tin đã công bố./

I declare that all information provided in this paper is true and accurate; I shall be legally responsible for any misrepresentation.

Người Ủy Quyền CBTT
Party authorized to disclose information



CN. Nguyễn Quốc Định

Số: 1C /UQ-IMP

Đồng Tháp, ngày 01 tháng 01 năm 2020

GIẤY ỦY QUYỀN

Người ủy quyền: Bà Trần Thị Đào

- Sinh ngày: 01/5/1952
- Địa chỉ: Số 04 đường 30/4, Phường 1, TP. Cao Lãnh, tỉnh Đồng Tháp
- Chức vụ: Tổng Giám đốc Công ty Cổ phần Dược phẩm Imexpharm
- Chứng minh nhân dân: 340580662
- Cấp ngày: 12/12/2012
- Nơi cấp: Công An Đồng Tháp

Người nhận ủy quyền: Ông Nguyễn Quốc Định

- Sinh năm: 1962
- Địa chỉ: Số 04 đường 30/4, Phường 1, TP. Cao Lãnh, tỉnh Đồng Tháp
- Chức vụ: Phó Tổng Giám đốc Công ty Cổ phần Dược phẩm Imexpharm
- Chứng minh nhân dân: 340246886
- Cấp ngày: 12/12/2012
- Nơi cấp: Công An Đồng Tháp

*** Nội dung ủy quyền:**

Người nhận ủy quyền được đại diện Công ty Cổ phần Dược phẩm Imexpharm thực hiện các công việc sau:


1. Ký các báo cáo tài chính, tài liệu, hồ sơ liên quan đến hoạt động tài chính của Công ty;
2. Ký các báo cáo thuế, tài liệu, hồ sơ liên quan đến thuế và Hải quan;
3. Ký các hợp đồng, tài liệu, hồ sơ liên quan đến việc gửi tiền, vay tiền, bảo lãnh, thế chấp, thanh toán nội địa, thanh toán quốc tế và các thủ tục khác tại các ngân hàng.

*** Thời gian ủy quyền:** Kể từ ngày ký ủy quyền cho đến khi có văn bản khác thay thế.

*** Trách nhiệm của người nhận ủy quyền:**

Ông Nguyễn Quốc Định được thực hiện các nội dung ủy quyền trên và chịu trách nhiệm trong phạm vi được ủy quyền.

NGƯỜI NHẬN ỦY QUYỀN



CN. Nguyễn Quốc Định

NGƯỜI ỦY QUYỀN



ĐS. Trần Thị Đào



Ngày 01 tháng 07 năm 2022

GIẤY ỦY QUYỀN

Tôi là Đinh Thị Quỳnh Vân, Tổng Giám đốc và Đại diện theo pháp luật của Công ty TNHH PwC (Việt Nam) (**Công ty**), mã số doanh nghiệp 0100157406, đăng ký lần đầu ngày 07 tháng 03 năm 2009 tại Sở Kế hoạch và Đầu tư Thành phố Hồ Chí Minh,

sau đây bổ nhiệm Ông Nguyễn Hoàng Nam, chứng minh nhân dân số 025598241, cấp ngày 08 tháng 02 năm 2012 (**Người đại diện theo ủy quyền**)

là Người đại diện theo ủy quyền hợp pháp và hợp lệ của tôi, thay mặt tôi và trên danh nghĩa của tôi:

thực hiện các công việc cụ thể như sau

- (i) ký, ban hành và chuyển giao các tài liệu sau của Công ty (có hoặc không có đóng dấu của Công ty):
 - thư xác nhận dịch vụ, hợp đồng và bảng báo phí dịch vụ cho khách hàng;
 - báo cáo, ý kiến, tư vấn, văn bản, thư từ hoặc tài liệu khác được ban hành theo hoặc liên quan đến thư xác nhận dịch vụ, hợp đồng, bảng báo phí dịch vụ, bao gồm giấy báo nợ, hóa đơn cho dịch vụ cung cấp;
- (ii) thực hiện các công việc khác liên quan đến các tài liệu nêu trên.

Tôi xác nhận rằng Người đại diện theo ủy quyền có quyền hợp pháp đại diện tôi thực hiện các công việc ủy quyền trên.

Giấy ủy quyền này có hiệu lực từ ngày ký đến hết ngày 30 tháng 06 năm 2023, trừ khi Người đại diện theo ủy quyền thôi làm việc cho Công ty, hoặc khi tôi ra quyết định chấm dứt việc ủy quyền sớm hơn.

Chữ ký người ủy quyền



Đinh Thị Quỳnh Vân
Tổng Giám đốc/Đại diện theo pháp luật

IMEXPHARM CORPORATION

**INTERIM FINANCIAL STATEMENTS
FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2022**

IMEXPHARM CORPORATION

**INTERIM FINANCIAL STATEMENTS
FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2022**

TABLE OF CONTENTS	PAGE
Corporate information	1
Statement by the Board of Management	2
Report on review of interim financial information	3
Interim balance sheet (Form B 01a - DN)	5
Interim income statement (Form B 02a - DN)	8
Interim cash flow statement (Form B 03a - DN)	9
Notes to the interim financial statements (Form B 09a - DN)	10

IMEXPHARM CORPORATION

CORPORATE INFORMATION

Enterprise registration certificate

No. 1400384433 was initially issued by the Department of Planning and Investment of Dong Thap Province on 1 August 2001 and the latest 29th amendment dated 20 October 2020.

Board of Directors

Mr. Nguyen Quoc Dinh	Chairman
Mrs. Tran Thi Dao	Vice chairman
Mr. Le Van Nha Phuong	Member
Mr. Truong Minh Hung	Member
Mr. Ngo Minh Tuan	Member
Mr. Tran Anh Tuan	Member
	(to 24 May 2022)
Mrs. Han Thi Khanh Vinh	Member

Board of Supervision

Mrs. Le Thi Kim Chung	Chief Supervisor
	(from 25 April 2022)
Mr. Nguyen Duc Tuan	Chief Supervisor
	(to 25 April 2022)
Mrs. Le Thi Kim Chung	Member
	(to 25 April 2022)
Mrs. Do Thi Thanh Thuy	Member

Board of Management

Mrs. Tran Thi Dao	General Director
Mr. Nguyen Quoc Dinh	Deputy General Director
Mr. Huynh Van Nhung	Deputy General Director
Mr. Ngo Minh Tuan	Deputy General Director
Mr. Le Van Nha Phuong	Deputy General Director
Mr. Tran Hoai Hanh	Chief Accountant

Legal representative

Mrs. Tran Thi Dao	General Director
-------------------	------------------

Registered office

No 4, 30/4 Street, Ward 1, Cao Lanh City,
Dong Thap Province, Vietnam

Auditor

PwC (Vietnam) Limited

IMEXPHARM CORPORATION

STATEMENT OF THE BOARD OF MANAGEMENT

Statement of the responsibility of the Board of Management of the Company in respect of the interim financial statements

The Board of Management of Imexpharm Corporation ("the Company") is responsible for preparing interim financial statements which give a true and fair view of the financial position of the Company as at 30 June 2022, and of the results of its operations and its cash flows for the six-month period then ended. In preparing these interim financial statements, the Board of Management is required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent; and
- prepare the interim financial statements on a going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Board of Management is responsible for ensuring that proper accounting records are kept which disclose, with reasonable accuracy at any time, the financial position of the Company and which enable interim financial statements to be prepared which comply with the basis of accounting set out in Note 2 to the interim financial statements. The Board of Management is also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud or errors.

The Legal Representative authorised the Deputy General Director of the Company to approve the financial statements for the six-month period ended 30 June 2022 in accordance with the Power of Attorney dated 1 January 2020.

Approval of the Interim Financial Statements

We hereby approve the accompanying interim financial statements as set out on pages 5 to 47 which give a true and fair view of the financial position of the Company as at 30 June 2022, and of the results of its operations and its cash flows for the six-month period then ended in accordance with Vietnamese Accounting Standards, the Vietnamese Corporate Accounting System and applicable regulations on preparation and presentation of interim financial statements.

On behalf of the Board of Management



Nguyen Quoc Dinh
Deputy General Director
Authorised by Legal Representative

Dong Thap Province, SR Vietnam
9 August 2022



REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION TO THE SHAREHOLDERS OF IMEXPHARM CORPORATION

We have reviewed the accompanying interim financial statements of Imexpharm Corporation ("the Company") which were prepared on 30 June 2022 and approved by the Board of Management on 9 August 2022. The interim financial statements comprise the interim balance sheet as at 30 June 2022, the interim income statement, and the interim cash flow statement for the six-month period then ended, and explanatory notes to the interim financial statements including significant accounting policies, as set out on pages 5 to 47.

Responsibility of the Board of Management

The Board of Management of the Company is responsible for the preparation and the true and fair presentation of these interim financial statements in accordance with Vietnamese Accounting Standards, the Vietnamese Corporate Accounting System and applicable regulations on preparation and presentation of interim financial statements and for such internal control which the Board of Directors determines is necessary to enable the preparation and fair presentation of interim financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on the interim financial statements based on our review. We conducted our review in accordance with Vietnamese Standard on Review Engagement 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity.

A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Vietnamese Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Auditor's Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim financial statements are not presented fairly, in all material respects, the financial position of the Company as at 30 June 2022, its financial performance and cash flows for the six-month period then ended in accordance with Vietnamese Accounting Standards, the Vietnamese Corporate Accounting System and applicable regulations on preparation and presentation of interim financial statements.

Other Matter

The report on review of interim financial statements is prepared in Vietnamese and English. Should there be any conflict between the Vietnamese and English versions, the Vietnamese version shall take precedence.

For and on behalf of PwC (Vietnam) Limited



Nguyen Hoang Nam
Audit Practising Licence No.
0849-2018-006-1
Authorised signatory

Report reference number: HCM12604
Ho Chi Minh City, 9 August 2022

INTERIM BALANCE SHEET

Code	ASSETS	Note	As at	
			30.6.2022 VND	31.12.2021 VND
100	CURRENT ASSETS		936,385,843,656	1,176,339,787,490
110	Cash and cash equivalents	3	67,242,992,545	271,272,865,376
111	Cash		47,242,992,545	46,272,865,376
112	Cash equivalents		20,000,000,000	225,000,000,000
120	Short-term investments		176,300,000,000	112,452,800,000
121	Trading securities		-	1,532,736,844
122	Provision for diminution in value of trading securities		-	(379,936,844)
123	Investments held to maturity	4(a)	176,300,000,000	111,300,000,000
130	Short-term receivables		264,965,470,307	295,062,515,167
131	Short-term trade accounts receivable	5	184,300,742,620	247,015,200,965
132	Short-term prepayments to suppliers	6	24,047,374,189	17,786,828,766
135	Short-term lending	7	18,083,980,000	2,000,000,000
136	Other short-term receivables	8	44,059,218,905	40,711,862,178
137	Provision for doubtful debts – short-term	9	(5,525,845,407)	(12,451,376,742)
140	Inventories		424,349,426,301	492,074,917,415
141	Inventories	10	428,268,748,050	493,805,074,580
149	Provision for decline in value of inventories	10	(3,919,321,749)	(1,730,157,165)
150	Other current assets		3,527,954,503	5,476,689,532
151	Short-term prepaid expenses		1,237,065,582	3,155,165,762
152	Value Added Tax ("VAT") to be reclaimed	16(a)	2,290,888,921	2,321,523,770

The notes on pages 10 to 47 are an integral part of these interim financial statements.

INTERIM BALANCE SHEET
(continued)

Code	ASSETS (continued)	Note	As at	
			30.6.2022 VND	31.12.2021 VND
200	LONG-TERM ASSETS		1,160,845,081,640	1,118,360,467,816
210	Long-term receivables		50,244,740	50,244,740
216	Other long-term receivables		50,244,740	50,244,740
220	Fixed assets		502,780,174,955	509,799,233,736
221	Tangible fixed assets	11(a)	429,685,378,562	436,217,826,957
222	Historical cost		921,860,260,102	900,574,257,505
223	Accumulated depreciation		(492,174,881,540)	(464,356,430,548)
227	Intangible fixed assets	11(b)	73,094,796,393	73,581,406,779
228	Historical cost		98,719,023,019	98,719,023,019
229	Accumulated amortisation		(25,624,226,626)	(25,137,616,240)
240	Long-term asset in progress		555,208,954,558	519,462,645,260
242	Construction in progress	12	555,208,954,558	519,462,645,260
250	Long-term investments		71,286,717,350	50,962,461,050
252	Investments in associates	4(b)	70,948,582,700	50,621,446,700
253	Investments in other entities	4(b)	617,550,000	617,550,000
254	Provision for long-term investments	4(b)	(279,415,350)	(276,535,650)
260	Other long-term asset		31,518,990,037	38,085,883,030
261	Long-term prepaid expenses	13	31,518,990,037	38,085,883,030
270	TOTAL ASSETS		2,097,230,925,296	2,294,700,255,306

The notes on pages 10 to 47 are an integral part of these interim financial statements.


INTERIM BALANCE SHEET
(continued)

Code	RESOURCES	Note	As at	
			30.6.2022 VND	31.12.2021 VND
300	LIABILITIES		327,110,925,898	500,290,192,302
310	Short-term liabilities		327,110,925,898	408,638,192,302
311	Short-term trade accounts payable	14	61,597,266,190	92,712,787,659
312	Short-term advances from customers	15	24,599,575,564	25,374,390,853
313	Tax and other payables to the State	16(b)	19,600,063,622	19,616,861,640
314	Payable to employees		24,509,633,493	36,173,686,395
315	Short-term accrued expenses	17	42,754,931,323	41,030,737,890
318	Short-term unearned revenue	18	27,164,210,569	-
319	Other short-term payables	19	2,943,851,343	4,794,695,249
320	Short-term borrowings	20(a)	93,600,000,000	172,142,789,243
322	Bonus and welfare fund	21	30,341,393,794	16,792,243,373
330	Long-term liabilities		-	91,652,000,000
338	Long-term borrowings	20(b)	-	91,652,000,000
400	OWNERS' EQUITY		1,770,119,999,398	1,794,410,063,004
410	Capital and reserves		1,770,119,999,398	1,794,410,063,004
411	Owners' capital	22, 23	667,053,700,000	667,053,700,000
411a	- Ordinary shares with voting rights		667,053,700,000	667,053,700,000
412	Share premium	23	507,368,247,904	507,368,247,904
414	Owners' other capital	23	2,420,789,142	2,420,789,142
415	Treasury shares	23	(358,600,000)	(358,600,000)
418	Investment and development fund	23	484,238,474,832	420,501,550,420
421	Undistributed earnings	23	109,397,387,520	197,424,375,538
421a	- Undistributed post-tax profits of previous years		1,623,268,980	414,907,353
421b	- Post-tax profits of current period/year		107,774,118,540	197,009,468,185
440	TOTAL RESOURCES		2,097,230,925,296	2,294,700,255,306


Duong Hoang Vu
Preparer


Tran Hoai Hanh
Chief Accountant




Nguyen Quoc Dinh
Deputy General Director
Authorised by Legal
Representative
9 August 2022


The notes on pages 10 to 47 are an integral part of these interim financial statements.

INTERIM INCOME STATEMENT

Code		Note	For the six-month period ended	
			30.6.2022 VND	30.6.2021 VND
01	Revenue from sales of goods		671,802,151,221	622,835,214,756
02	Less deductions		(3,105,395,572)	(8,973,991,134)
10	Net revenue from sales of goods	27	668,696,755,649	613,861,223,622
11	Cost of goods sold	28	(384,967,092,856)	(353,222,253,056)
20	Gross profit from sales of goods		283,729,662,793	260,638,970,566
21	Financial income	29	13,538,102,398	4,558,468,205
22	Financial expenses	30	(13,696,146,600)	(9,917,863,089)
23	- Including: Interest expense	30	(2,192,395,206)	(2,706,399,236)
25	Selling expenses	31	(114,913,529,509)	(109,085,615,776)
26	General and administration expenses	32	(43,892,351,794)	(33,495,643,565)
30	Net operating profit		124,765,737,288	112,698,316,341
31	Other income		558,027,718	5,369,394,163
32	Other expenses		(81,057,519)	(1,121,825,690)
40	Net other income		476,970,199	4,247,568,473
50	Net accounting profit before tax		125,242,707,487	116,945,884,814
51	Corporate income tax - current	33	(26,029,283,306)	(25,765,888,978)
52	Corporate income tax - deferred	33	-	-
60	Net profit after tax		99,213,424,181	91,179,995,836
70	Basic earnings per share	25	1,310	1,266
71	Diluted earnings per share	25	1,310	1,266


Duong Hoang Vu
Preparer


Tran Hoai Hanh
Chief Accountant


Nguyen Quoc Dinh
Deputy General Director
Authorised by Legal
Representative
9 August 2022

The notes on pages 10 to 47 are an integral part of these interim financial statements.

INTERIM CASH FLOW STATEMENT
(Indirect method)

		For the six-month period ended	
Code	Note	30.6.2022 VND	30.6.2021 VND
CASH FLOWS FROM OPERATING ACTIVITIES			
01		125,242,707,487	116,945,884,814
Net profit before tax			
Adjustments for:			
02	11	30,176,403,086	29,769,091,890
03		(5,113,423,895)	(3,252,172,611)
04	30, 29	2,279,366,772	(62,249,701)
05		(7,686,248,415)	(8,594,433,028)
06	30	2,192,395,206	2,706,399,236
08		147,091,200,241	137,512,520,600
Operating profit before changes in working capital			
09		48,497,599,015	41,431,567,242
10		65,536,326,530	(28,480,553,190)
11		(18,254,893,368)	5,888,197,260
12		8,484,993,173	6,403,561,458
13		1,532,736,844	-
14		(2,899,026,217)	(1,551,956,269)
15	16	(30,526,027,664)	(26,011,659,863)
17		(9,946,982,366)	(32,205,465,391)
20		209,515,926,188	102,986,211,847
CASH FLOWS FROM INVESTING ACTIVITIES			
21		(53,318,653,100)	(34,926,425,840)
22		564,545,455	8,655,454,545
23		(215,383,980,000)	(145,049,478,082)
24		134,300,000,000	103,525,985,667
25		(20,327,136,000)	-
27		12,336,828,344	2,712,066,396
30		(141,828,395,301)	(65,082,397,314)
CASH FLOWS FROM FINANCING ACTIVITIES			
33		22,373,528,572	244,294,331,030
34		(194,084,317,815)	(175,056,437,784)
36	24	(100,007,355,000)	-
40		(271,718,144,243)	69,237,893,246
50		(204,030,613,356)	107,141,707,779
60	3	271,272,865,376	85,268,705,365
61		740,525	(215,577,365)
70	3	67,242,992,545	192,194,835,779

Major non-cash transactions in the six-month period ended 30 June 2022 are presented in Note 36.

Duong Hoang Vu
Preparer

Tran Hoai Hanh
Chief Accountant

Nguyen Quoc Dinh
Deputy General Director
Authorised by Legal
Representative
9 August 2022

The notes on pages 10 to 47 are an integral part of these interim financial statements.

**NOTES TO THE INTERIM FINANCIAL STATEMENTS
FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2022**

1 GENERAL INFORMATION

Imexpharm Corporation ("the Company"), formerly known as Dong Thap Pharmaceutical Union incorporated under Decision No. 284/TCCQ dated 28 September 1983 issued by the Health Department of Dong Thap Province, was transformed from a State-Owned company into a joint stock company in accordance with initial Enterprise registration certificate No. 1400384433 dated 1 August 2001 and the latest 29th amendment dated 20 October 2020 issued by the Department of Planning and Investment of Dong Thap Province.

The Company's shares were listed on Ho Chi Minh Stock Exchange ("HOSE") on 15 November 2006 with the stock code IMP under Decision No. 76/UBCK-GPNY of HOSE.

The principal activities of the Company are manufacturing pharmaceutical products, processing pharmaceutical materials, trading, importing and exporting pharmaceutical products, medical equipment and supplies, chemicals, materials for medicine manufacturing and packaging, chemicals used for sterilization or disinfection in humans (except for those listed under Point A, Part II, Appendix No. 4 accompanying Decision No. 10/2007/QĐ-BTM dated 21 May 2007 issued by the Ministry of Trade, currently known as the Ministry of Industry and Trade).

The normal business cycle of the Company is 12 months.

As at 30 June 2022, the Company had 25 branches and 3 associates as presented in Note 4(b) – Investments. Details of the Company's associates are presented below:

Company name	Principal activities	Address of registered office	Percentage of ownership and voting rights	
			30.6.2022	31.12.2022
Agimexpharm Pharmaceutical Joint Stock Company	Manufacturing and trading pharmaceutical products	An Giang Province	32.99%	32.99%
Dong Thap Muoi Research Conservation and Development Pharmaceutical Joint Stock Company	Researching, conserving, and developing pharmaceutical materials	Long An Province	23.56%	23.56%
Gia Dai Pharmaceutical Company Limited	Manufacturing and trading pharmaceutical products	Ho Chi Minh City	26.00%	26.00%

As at 30 June 2022, the Company had 1,225 employees (as at 31 December 2021: 1,203 employees).

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**2.1 Basis of preparation of interim financial statements**

The interim financial statements have been prepared in accordance with Vietnamese Accounting Standards, the Vietnamese Corporate Accounting System and applicable regulations on preparation and presentation of interim financial statements. The interim financial statements have been prepared under the historical cost convention.

The accompanying interim financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles and practices generally accepted in countries and jurisdictions other than Vietnam. The accounting principles and practices utilised in Vietnam may differ from those generally accepted in countries and jurisdictions other than Vietnam.

The interim financial statements in Vietnamese language are the official statutory financial statements of the Company. The interim financial statements in English language have been translated from the Vietnamese version.

2.2 Fiscal year

The Company's fiscal year is from 1 January to 31 December.

The interim financial statements have been prepared for the accounting period from 1 January 2022 to 30 June 2022.

2.3 Currency

The financial statements are measured and presented in Vietnamese Dong ("VND").

2.4 Exchange rates

Transactions arising in foreign currencies are translated at exchange rates ruling at the transaction dates. Foreign exchange differences arising from these transactions are recognised as income or expenses in the income statement.

Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are respectively translated at the buying and selling exchange rates at the balance sheet date of the commercial bank where the Company regularly trades. Foreign currencies deposited in bank at the balance sheet date are translated at the buying exchange rate of the commercial bank where the Company opens its foreign currency accounts. Foreign exchange differences arising from these translations are recognised in the interim income statement.

2.5 Cash and cash equivalents

Cash and cash equivalents comprise cash on hand, cash at bank, cash in transit, demand deposits and other short-term investments with an original maturity of three months or less.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**2.6 Receivables**

Receivables represent trade receivables from customers arising from sales of goods or non-trade receivables from others and are stated at cost. Provision for doubtful debts is made for each outstanding amount based on overdue days in payment according to the initial payment commitment (exclusive of the payment rescheduling between parties) or based on the estimated losses that may arise. Bad debts are written off when identified as uncollectible.

Receivables are classified into short-term and long-term receivables on the balance sheet based on the remaining period from the balance sheet date to the maturity date.

2.7 Inventories

Inventories are stated at the lower of cost and net realisable value. Cost is determined by the weighted average method and includes all costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition. In the case of manufactured products, cost includes all direct expenditure and production overheads based on normal levels of operating activity. Net realisable value is the estimated selling price in the normal course of business, less the estimated costs of completion and selling expenses.

The Company applies the perpetual method for inventories.

Provision is made, where necessary, for obsolete, slow-moving, and defective inventory items. The difference between the provision of this period and the provision of the previous period are recognised as an increase or decrease of operating expenses in the period.

2.8 Investments**(a) Trading securities**

Trading securities are securities, which are held for trading to earn profit.

Trading securities are initially recorded at historical cost including cost of acquisition and any expenditure that is directly attributable to the acquisition. Subsequently, the Board of Management reviews all outstanding investments to determine the amount of provision to recognise at the period end. The provision for diminution in value of trading securities is made when their cost is higher than their fair value. Changes in the provision balance during the accounting fiscal period are recorded as an increase or decrease in financial expenses. A reversal, if any, is made only to the extent the investment is restored to its original cost.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**2.8 Investments (continued)****(a) Trading securities (continued)**

The Company recognises trading securities when it has ownership of the assets, specifically as follows:

- Listed securities are recognised at the time of order matching; and
- Unlisted securities are recognised at the time when official ownership is established in accordance with regulations.

Profit or loss from liquidation or disposal of trading securities is recorded in the interim income statement. The costs of trading securities disposed are determined by using the moving weighted average method.

(b) Investments held to maturity

Investments held to maturity are investments which the Company has positive intention and ability to hold until maturity.

Investments held to maturity include term deposits and other investments held to maturity. Those investments are initially accounted for at cost. Subsequently, the Board of Management reviews all outstanding investments to determine the amount of provision to recognise at the period end.

Provision for diminution in value of investments held to maturity is made when there is evidence that the investment is uncollectible in whole or in part. Changes in the provision balance during the accounting fiscal period are recorded as an increase or decrease in financial expenses. A reversal, if any, is made only to the extent the investment is restored to its original cost.

Investments held to maturity are classified into short-term and long-term investments held to maturity on the balance sheet based on the remaining period from the balance sheet date to the maturity date.

(c) Investments in associates

Associates are investments that the Company has significant influence but not control and would generally have from 20% to under 50% of the voting rights of the investee. Investments in associates are initially recorded at cost of acquisition including purchase cost plus other expenditure directly attributable to the investments. Subsequently, the Board of Management reviews all outstanding investments to determine the amount of provision to recognise at the period end.

(d) Investments in other entities

Investments in other entities are investments in equity instruments of other entities without controlling rights or co-controlling rights, or without significant influence over the investee. These investments are accounted for initially at cost. Subsequently, the Board of Management reviews all outstanding investments to determine the amount of provision to recognise at the period end.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**2.8 Investment (continued)****(e) Provision for investments in associates and other entities**

Provision for investments in associates and other entities is made when there is a diminution in value of the investments at the period end. Regarding investments in listed shares or those whose fair value can be determined reliably, the provision for diminution in value is made when the cost is higher than market value. For other investments, provision for diminution in value is made when the investees make losses.

Changes in the provision balance during the accounting period are recorded as an increase or decrease in financial expenses. A reversal, if any, is made only to the extent the investment is restored to its original cost.

2.9 Lending

Lending is loan granted for interest earning granted under agreements among parties but not being traded as securities.

Lending is initially recognised at cost. Subsequently, the Board of Management reviews all outstanding amounts to determine the amount of provision to recognise for the six-month period.

Provision for doubtful lending is made for each lending based on overdue days in payment of principals according to the initial payment commitment (exclusive of the payment rescheduling between parties) or based on the estimated losses that may arise. Changes in the provision balance during the accounting period are recorded as an increase or decrease in financial expenses. A reversal, if any, is made only to the extent the investment is restored to its original cost.

Lending is classified into short-term and long-term lending on the interim balance sheet based on the remaining term of the lending as at the balance sheet date.

2.10 Fixed assets*Tangible and intangible fixed assets*

Fixed assets are stated at historical cost less accumulated depreciation or amortisation. Historical cost includes any expenditure that is directly attributable to the acquisition of the fixed assets bringing them to suitable conditions for their intended use. Expenditure incurred subsequently which has resulted in an increase in the future economic benefits expected to be obtained from the use of fixed assets, can be capitalised as an additional historical cost. Otherwise, such expenditure is charged to the income statement when incurred.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**2.10 Fixed assets (continued)***Depreciation and amortisation*

Fixed assets are depreciated and amortised using the straight-line method so as to write off the historical cost of the fixed assets over their estimated useful lives or over the term of the enterprise registration certificate if shorter. The estimated useful lives of each asset class are as follows:

Plant, buildings, and structures	5 – 40 years
Machinery and equipment	3 – 15 years
Motor vehicles	5 – 10 years
Office equipment	3 – 8 years
Computer software	3 – 5 years
Copyright	3 years
Others	3 years

Land use rights are comprised of land use rights with an indefinite useful life and land use rights with a definite useful life as follows:

- Land use rights with an indefinite useful life are recorded at historical cost and are not amortised; and
- Land use rights with a definite useful life are recorded in accordance with the terms indicated in the land use rights certificate and amortised using the straight-line method in accordance with such land use rights certificates.

Disposals

Gains or losses on disposals are determined by comparing net disposal proceeds with the carrying amount of the fixed assets and are recognised as income or expense in the interim income statement.

Construction in progress

Construction in progress represents the cost of assets in the course of construction for production, rental or administrative purposes, or for purposes not yet determined, which are recorded at cost and are comprised of such necessary costs to newly construct, to repair and maintain, to upgrade, to renew or equip the projects with technologies as construction costs; costs of tools and equipment; project management expenditures; construction consulting expenditures; and capitalised borrowing costs for qualifying assets in accordance with the Company's accounting policies. Depreciation of these assets, on the same basis as other fixed assets, commences when they are ready for their intended use.

2.11 Operating leases

Leases where a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to the interim income statement on a straight-line basis over the term of the lease.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**2.12 Prepaid expenses**

Prepaid expenses include short-term and long-term prepayments on the interim balance sheet. Prepaid expenses are recorded at historical cost and allocated on straight-line basis over their estimated useful lives.

Prepayments for land rental contracts which are effective after the effective date of the land law 2003 or which land use right certificates are not granted are recorded as prepaid expenses and allocated using the straight-line method over the terms of such land use right certificates.

2.13 Payables

Classifications of payables are based on their nature as follows:

- Trade accounts payable are trade payables arising from purchase of goods and services.
- Other payables are non-trade payables and payables not relating to purchases of goods and services.

Payables are classified into short-term and long-term payables on the interim balance sheet based on the remaining period from the balance sheet date to the maturity date.

2.14 Borrowings

Borrowings include borrowings from banks.

Borrowings are classified into short-term and long-term on the interim balance sheet based on their remaining terms from the interim balance sheet date to the maturity date.

Borrowing costs that are directly attributable to the construction or production of any qualifying assets are capitalised during the period of time that is required to complete and prepare the asset for its intended use. In respect of general-purpose borrowings, a portion of which used for the purpose of construction or production of any qualifying assets, the Company determines the amount of borrowing costs eligible for capitalisation by applying a capitalisation rate to the weighted average expenditure on the assets. The capitalisation rate is the weighted average of the interest rates applicable to the Company's borrowings that are outstanding during the period, other than borrowings made specifically for the purpose of obtaining a qualifying asset. Other borrowing costs are recognised in the income statement when incurred.

2.15 Accrued expenses

Accrued expenses include liabilities for goods and services received in the period but not yet paid for due to pending invoices or insufficient records and documents. Accrued expenses are recorded as operating expenses in the reporting period.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**2.16 Provisions**

Provisions are recognised when the Company has a present legal or constructive obligation as a result of past events; it is probable that an outflow of resources will be required to settle the obligation and the amount has been reliably estimated. Provision is not recognised for future operating losses.

Provisions are measured at the expenditures expected to be required to settle the obligation. If the time value of money is material, provision will be measured at the present value using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the obligation. The increase in the provision due to passage of time is recognised as financial expenses. Changes in the provision balance during the accounting period are recorded as an increase or decrease in operating expenses.

2.17 Fund for scientific and technological development

Fund for scientific and technological development is appropriated for scientific and technological development activities. The fund is set up on the basis of maximum 10% of profit before tax and charged to operating expenses when appropriated.

2.18 Provision for severance allowances

In accordance with Vietnamese labour laws, employees of the Company who have worked regularly for full 12 months or longer, are entitled to a severance allowance. The working period used for the calculation of severance allowance is the period during which the employee works for the Company less the period during which the employee participates in the unemployment insurance scheme in accordance with the labour regulations and the working period for which the employee has received severance allowance from the Company.

The severance allowance is accrued at the end of the reporting period on the basis that each employee is entitled to half of an average monthly salary for each working year. The average monthly salary used for calculating severance allowance is the employee contract's average salary for the six-month period prior to the balance sheet date. As at 30 June 2022, the estimated provision for severance allowances to be accrued was VND10,568,755,000.

In accordance with the guidance of Circular No. 180/2012/TT-BTC dated 24 October 2012 issued by the Ministry of Finance, the Company does not recognise provision for severance allowances. The Company records and pays severance allowances when employees leave the Company.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**2.19 Capital and reserves**

Owners' capital is recorded according to the actual amounts contributed at the par value of the shares.

Share premium is the difference between the par value and the issue price of shares; the difference between the repurchase price and re-issuing price of treasury shares.

Owners' other capital represents other capital of the owners at the reporting date.

Treasury shares bought before the effective date of the Securities Law (ie. 1 January 2021) are shares issued by the Company and bought back by itself, but these are not cancelled and may be re-issued subsequently in accordance with the Law on Securities. Treasury shares bought after 1 January 2021 will be cancelled and adjusted to reduce equity.

Undistributed earnings record the Company's results after CIT at the reporting date.

2.20 Appropriation of profit

The Company's dividends are recognised as a liability in the Company's interim financial statements in the period in which the dividends are approved by the Company's General Meeting of shareholders.

Profit after CIT could be distributed to shareholders after approval at the General Meeting of shareholders, and after appropriation to other funds in accordance with the Company's charter and Vietnamese regulations.

The Company's funds are as below:

(a) Investment and development fund

Investment and development fund is appropriated from the Company's profit after CIT as approved by shareholders at the General Meeting of Shareholders. This fund is appropriated for investment and business expansion activities, and offsetting against damages incurred during the course of business (if any). The fund's disbursement is decided by the Board of Directors and the General Director depending on utilisation purpose.

(b) Bonus and welfare fund

Bonus and welfare fund is appropriated from the Company's profit after CIT and subject to shareholders' approval at the Company's General Meeting. This fund is presented as a liability on the interim balance sheet. The fund is set aside for the purpose of rewarding, encouragement, and improvement of the employees' welfare.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**2.21 Revenue recognition****(a) Revenue from sales of goods**

Revenue from sale of goods is recognised in the interim income statement when all five (5) following conditions are satisfied:

- The Company has transferred to the buyer the significant risks and rewards of ownership of the goods;
- The Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
- The amount of revenue can be measured reliably;
- It is probable that the economic benefits associated with the transaction will flow to the Company; and
- The costs incurred or to be incurred in respect of the transaction can be measured reliably.

No revenue is recognised if there are significant uncertainties regarding recovery of the consideration due or the possible return of goods.

Revenue is recognised in accordance with the "substance over form" principle and allocated to each sale obligation. In cases where the Company gives promotional goods to customers associated with their purchases, the Company allocates the total considerations received between goods sold and promotional goods. The cost of promotional goods is recognised as cost of goods sold in the interim income statement.

(b) Interest income

Interest income is recognised on an earned basis.

(c) Dividend income

Income from dividends is recognised when the Company has established the receiving rights from investees.

2.22 Sales deductions

Sales deductions include trade discounts, sales returns, and allowances. Sales deductions incurred in the same period of the related sales of products are recorded as deduction from the revenue of that period.

Sales deductions for sale of products and goods which are sold in the period but are incurred after the balance sheet date but before the issuance of the interim financial statements are recorded as a deduction from the revenue of the period.

2.23 Cost of goods sold

Cost of goods sold are cost of finished goods, merchandises and materials sold during the period, and recorded on the basis of matching with revenue and on a prudent basis.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**2.24 Financial expenses**

Financial expenses are expenses incurred in the period for financial activities including interest expenses, provision for diminution in value of investments in other entities and losses from foreign exchange differences and payment discounts.

2.25 Selling expenses

Selling expenses represent expenses incurred in the process of selling products, goods, and providing services.

2.26 General and administration expenses

General and administration expenses represent expenses incurred for administrative purposes.

2.27 Current and deferred income tax

Income taxes include all income taxes which are based on taxable profits including profits generated from production and trading activities in other countries with which the Socialist Republic of Vietnam has not signed any double taxation agreement. Income tax expense comprises current tax expense and deferred tax expense.

Current income tax is the amount of income taxes payable or recoverable in respect of the current period taxable profits at the current period tax rates. Current and deferred tax should be recognised as an income or an expense and included in the profit or loss of the period, except to the extent that the tax arises from a transaction or event which is recognised, in the same or a different period, directly in equity.

Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the interim financial statements. Deferred income tax is not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of occurrence affects neither the accounting nor the taxable profit or loss. Deferred income tax is determined at the tax rates that are expected to apply to the financial period when the asset is realised or the liability is settled, based on tax rates that have been enacted or substantively enacted by the balance sheet date.

Deferred income tax assets are recognised to the extent that it is probable that future taxable profits will be available against which the temporary differences can be utilised.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**2.28 Related parties**

Enterprises and individuals that directly, or indirectly through one or more intermediaries, control, or are controlled by, or are under common control with, the Company, including holding companies, subsidiaries and fellow subsidiaries are related parties of the Company. Associates and individuals owning, directly or indirectly, an interest in the voting power of the Company that gives them significant influence over the Company, key management personnel, including Boards of Directors and Board of Management of the Company and close members of the family of these individuals and companies associated with these individuals also constitute related parties.

In considering its relationships with each related party, the Company considers the substance of the relationship not merely the legal form.

2.29 Segment reporting

A segment is a component, which can be separated by the Company, engaged in sales of goods, or rendering of services (business segment) or sales of goods or rendering of services within a particular economic environment (geographical segment). Each segment is subject to risks and returns that are different from those of other segments. A reportable segment is the Company's business segment or the Company's geographical segment.

Segment reporting is prepared and presented in accordance with accounting policies applied to the preparation and presentation of the Company's interim financial statements in order to help users of interim financial statements understand and evaluate the Company's operations in a comprehensive manner.

2.30 Accounting estimates

The preparation of financial statements in conformity with Vietnamese Accounting Standards, the Vietnamese Corporate Accounting System and applicable regulations on preparation and presentation of financial statements requires the Board of Management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the date of the interim financial statements and the reported amounts of revenues and expenses during the period.

The areas involving significant estimates and assumptions are as follows:

- Estimation of provision for doubtful debt (Note 9);
- Estimation of provision for decline in value of inventories (Note 10); and
- Estimated useful life of fixed assets (Note 11).

Such estimates and assumptions are continually evaluated. They are based on historical experiences and other factors, including expectations of future events that may have a financial impact on the Company and that are believed to be reasonable under the circumstances.

3 CASH AND CASH EQUIVALENTS

	30.6.2022 VND	31.12.2021 VND
Cash on hand	1,620,270,759	2,220,458,913
Cash at bank	45,620,991,386	43,340,006,463
Cash in transit	1,730,400	712,400,000
Cash equivalents (*)	20,000,000,000	225,000,000,000
	<u>67,242,992,545</u>	<u>271,272,865,376</u>

(*) As at 30 June 2022, cash equivalents represent bank deposits with maturity of three months and earn interest at the fixed interest rates of 4% per annum (as at 31 December 2021: from 3.8% per annum to 4% per annum).

IMEXPHARM CORPORATION

Form B 09a – DN

4 INVESTMENTS

(a) Investments held to maturity

	30.6.2022		31.12.2021	
	Cost VND	Book value VND	Cost VND	Book value VND
Term deposits at banks	176,300,000,000	176,300,000,000	111,300,000,000	111,300,000,000

As at 30 June 2022, the term deposits represent bank deposits with maturity from six months to twelve months and earn interest at the fixed interest rate from 4.6% per annum to 5.7% per annum (as at 31 December 2021: from 4.6% per annum to 5.3% per annum).

(b) Long-term investments

	30.6.2022			31.12.2021		
	Cost VND	Fair value VND	Provision VND	Cost VND	Fair value VND	Provision VND
(i) Investments in associates						
Agimexpharm Pharmaceutical Joint Stock Company	66,958,582,700	115,768,685,947	-	46,631,446,700	102,342,894,940	-
Dong Thap Muoi Research Conservation and Development Pharmaceutical Joint Stock Company	3,808,000,000	-	-	3,808,000,000	-	-
Gia Dai Pharmaceutical Company Limited	182,000,000	-	(182,000,000)	182,000,000	-	(182,000,000)
	70,948,582,700	115,768,685,947	(182,000,000)	50,621,446,700	102,342,894,940	(182,000,000)

IMEXPHARM CORPORATION

Form B 09a – DN

4 INVESTMENTS (continued)

(b) Long-term investments (continued)

Operational status of associates

Gia Dai Pharmaceutical Company Limited stopped its operations in 2015. Other associates are operating in their normal course of business.

Fair value

As at 30 June 2022 and 31 December 2021, the fair value of investment in Agimexpharm Pharmaceutical Joint Stock Company was VND 115,768,685,947 and VND102,342,894,940, respectively. The Company has not determined the fair value of remaining investments since such information is not available.

	30.6.2022			31.12.2021		
	Cost VND	Fair value VND	Provision VND	Cost VND	Fair value VND	Provision VND
(ii) Investments in equity of other entities						
Vidipha Central Pharmaceutical Joint Stock Company	503,000,000	683,164,000	-	503,000,000	697,546,400	-
No. 25 Central Pharmaceutical Joint Stock Company	114,550,000	17,134,650	(97,415,350)	114,550,000	20,014,350	(94,535,650)
	<u>617,550,000</u>	<u>700,298,650</u>	<u>(97,415,350)</u>	<u>617,550,000</u>	<u>717,560,750</u>	<u>(94,535,650)</u>

Equity investments in other entities represent the investments that hold less than 20% voting rights in those entities.

5 SHORT-TERM TRADE ACCOUNTS RECEIVABLE

	30.6.2022 VND	31.12.2021 VND
Third parties (*)	178,537,743,243	244,719,287,253
Related parties (Note 37(b))	5,762,999,377	2,295,913,712
	<u>184,300,742,620</u>	<u>247,015,200,965</u>

(*) Details of customers accounting for 10% or more of total short-term trade accounts receivable balance are as follows:

	30.6.2022 VND	31.12.2021 VND
Orgalife Nutritional Science Co., Ltd.	22,800,016,720	43,743,402,089
JP Pharma JSC	17,921,551,200	9,368,362,500
Newzilan Trading JSC	<u>4,411,837,500</u>	<u>24,280,000,000</u>

As at 30 June 2022 and 31 December 2021, the balances of short-term trade accounts receivable which were past due, amounting to VND11,301,291,862 and VND9,253,737,611, respectively, and are presented in Note 9.

6 SHORT-TERM PREPAYMENTS TO SUPPLIERS

	30.6.2022 VND	31.12.2021 VND
Third parties (*)	<u>24,047,374,189</u>	<u>17,786,828,766</u>

(*) Details of suppliers accounting for 10% or more of total balance of short-term prepayments to suppliers are as follows:

	30.6.2022 VND	31.12.2021 VND
Teampack Import-Export Trading Service One Member Co., Ltd	5,830,806,080	1,457,701,520
New Diamond Machinery Co., Ltd	4,387,548,000	4,387,548,000
Qilu Antibiotics Pharmaceutical Co.	2,619,680,000	-
Orioled International Pte., Ltd.	-	2,186,940,700
Rieckermann Services Limited	-	<u>2,011,392,000</u>

7 SHORT-TERM LENDINGS

	30.6.2022 VND	31.12.2021 VND
Individuals	<u>18,083,980,000</u>	<u>2,000,000,000</u>

IMEXPHARM CORPORATION

Form B 09a – DN

8 OTHER SHORT-TERM RECEIVABLES

	30.6.2022		31.12.2021	
	Book value VND	Provision VND	Book value VND	Provision VND
Advances to employees	29,943,000,209	-	21,334,760,203	-
Interest income from banks	1,799,616,438	-	2,500,372,603	-
Others	12,316,602,258	(486,348,974)	16,876,729,372	(7,382,035,914)
	<u>44,059,218,905</u>	<u>(486,348,974)</u>	<u>40,711,862,178</u>	<u>(7,382,035,914)</u>

As at 30 June 2022 and 31 December 2021, the balances of other short-term receivables which were not past due but doubtful, amounting to VND486,348,974 and VND7,382,035,914, respectively, and are presented in Note 9.

9 DOUBTFUL DEBTS

	30.6.2022			31.12.2021		
	Cost VND	Recoverable amount VND	Provision VND	Cost VND	Recoverable amount VND	Provision VND
i) Receivables that were past due	11,301,291,862	6,261,795,429	(5,039,496,433)	9,253,737,611	4,184,396,784	(5,069,340,828)
From 6 months to 1 year	7,701,182,984	5,390,828,089	(2,310,354,895)	4,109,887,691	2,876,921,384	(1,232,966,307)
From 1 year to 2 years	1,112,389,924	556,194,962	(556,194,962)	1,553,349,079	776,674,540	(776,674,540)
From 2 years to 3 years	1,049,241,260	314,772,378	(734,468,882)	617,375,227	185,212,568	(432,162,659)
Over 3 years	1,438,477,694	-	(1,438,477,694)	2,973,125,614	345,588,292	(2,627,537,322)
ii) Receivables that were not past due but doubtful	486,348,974	-	(486,348,974)	7,382,035,914	-	(7,382,035,914)
	<u>11,787,640,836</u>	<u>6,261,795,429</u>	<u>(5,525,845,407)</u>	<u>16,635,773,525</u>	<u>4,184,396,784</u>	<u>(12,451,376,742)</u>

10 INVENTORIES

	30.6.2022		31.12.2021	
	Cost VND	Provision VND	Cost VND	Provision VND
Raw materials	262,379,268,068	(3,653,884,847)	332,440,599,219	(1,730,157,165)
Finished goods	127,475,918,504	(265,436,902)	123,745,850,735	-
Work in progress	28,891,831,094	-	28,558,844,869	-
Goods in transit	3,495,409,138	-	3,912,299,583	-
Tools and supplies	3,411,103,145	-	3,626,904,362	-
Merchandise	2,615,218,101	-	1,520,575,812	-
	<u>428,268,748,050</u>	<u>(3,919,321,749)</u>	<u>493,805,074,580</u>	<u>(1,730,157,165)</u>

Movements in the provision for decline in value of inventories during the period/year were as follows:

	For the six-month period ended 30.6.2022 VND	For the year ended 31.12.2021 VND
Beginning of period/year	1,730,157,165	3,438,627,849
Increase (Note 28)	2,189,164,584	-
Reversal (Note 28)	-	(1,708,470,684)
End of period/year	<u>3,919,321,749</u>	<u>1,730,157,165</u>

IMEXPHARM CORPORATION

Form B 09a – DN

11 FIXED ASSETS

(a) Tangible fixed assets

	Plant, buildings and structure VND	Machinery and equipment VND	Motor vehicles VND	Office equipment VND	Total VND
Historical cost					
As at 1 January 2022	298,601,760,400	459,910,580,956	97,851,331,274	44,210,584,875	900,574,257,505
New purchases	151,349,000	4,654,798,364	1,419,500,000	298,241,735	6,523,889,099
Transfers from construction in progress (Note 12)	-	12,084,163,369	4,563,886,585	560,587,544	17,208,637,498
Disposals	-	(237,824,000)	(2,208,700,000)	-	(2,446,524,000)
As at 30 June 2022	298,753,109,400	476,411,718,689	101,626,017,859	45,069,414,154	921,860,260,102
Accumulated depreciation					
As at 1 January 2022	124,532,036,144	239,375,699,062	70,436,089,986	30,012,605,356	464,356,430,548
Charge for the period	5,190,986,723	18,403,224,231	3,431,347,874	2,664,233,872	29,689,792,700
Disposals	-	(237,824,000)	(1,633,517,708)	-	(1,871,341,708)
As at 30 June 2022	129,723,022,867	257,541,099,293	72,233,920,152	32,676,839,228	492,174,881,540
Net book value					
As at 1 January 2022	174,069,724,256	220,534,881,894	27,415,241,288	14,197,979,519	436,217,826,957
As at 30 June 2022	169,030,086,533	218,870,619,396	29,392,097,707	12,392,574,926	429,685,378,562

As at 30 June 2022, tangible fixed assets with a carrying value of VND72,040,808,865 were pledged with banks as collateral assets for long-term borrowings granted to the Company (Note 20) (as at 31 December 2021: VND77,224,193,967).

Historical cost of fully depreciated tangible fixed assets but still in use as at 30 June 2022 was VND255,580,752,325 (as at 31 December 2021: VND249,972,738,561).

IMEXPHARM CORPORATION

Form B 09a – DN

11 FIXED ASSETS (continue)

(b) Intangible fixed assets

	Land use rights VND	Copyright VND	Computer software VND	Others VND	Total VND
Historical cost					
As at 1 January 2022 and 30 June 2022	80,217,869,328	744,712,823	15,666,460,868	2,089,980,000	98,719,023,019
Accumulated amortisation					
As at 1 January 2022	7,198,537,295	744,712,823	15,460,575,010	1,733,791,112	25,137,616,240
Charge for the period	293,501,191	-	85,142,527	107,966,668	486,610,386
As at 30 June 2022	7,492,038,486	744,712,823	15,545,717,537	1,841,757,780	25,624,226,626
Net book value					
As at 1 January 2022	73,019,332,033	-	205,885,858	356,188,888	73,581,406,779
As at 30 June 2022	72,725,830,842	-	120,743,331	248,222,220	73,094,796,393

Historical cost of fully amortised intangible fixed assets but still in use as at 30 June 2022 was VND 17,626,981,691 (as at 31 December 2021: VND17,285,601,899).

12 CONSTRUCTION IN PROGRESS

	30.6.2022 VND	31.12.2021 VND
Purchases of machinery and equipment	446,900,277,914	416,207,494,483
High-technology pharmaceutical factory	70,236,170,248	69,141,549,239
Others	38,072,506,396	34,113,601,538
	<u>555,208,954,558</u>	<u>519,462,645,260</u>

As at 30 June 2022 and as at 31 December 2021, machinery, and equipment with a carrying value of VND196,487,625,046 were pledged with banks as collateral assets for long-term borrowings granted to the Company (Note 20).

Movements in the construction in progress during the period/year are as follows:

	For the six-month period ended 30.6.2022 VND	For the year ended 31.12.2021 VND
Beginning of period/year	519,462,645,260	522,446,935,889
Purchase	52,954,946,796	49,079,825,363
Transfers to tangible fixed assets (Note 11(a))	(17,208,637,498)	(51,904,743,992)
Transfers to intangible fixed assets	-	(159,372,000)
End of period/year	<u>555,208,954,558</u>	<u>519,462,645,260</u>

12 LONG-TERM PREPAID EXPENSES

	30.6.2022 VND	31.12.2021 VND
Product circulation licenses	9,043,175,791	11,943,130,894
Land rental	12,051,948,654	10,927,573,418
Quality evaluation costs (*)	1,655,239,444	4,363,306,459
Tools and supplies	3,414,568,333	3,986,230,264
Office furniture	2,031,327,841	2,554,393,122
Others	3,322,729,974	4,311,248,873
	<u>31,518,990,037</u>	<u>38,085,883,030</u>

(*) Included the costs incurred in order to obtain the EU-GMP certification for the production lines at high-tech antibiotic factories. The EU-GMP certification is valid for a period of 3 years. These expenses shall be allocated over this period accordingly.

13 LONG-TERM PREPAID EXPENSES (continued)

Movements in long-term prepaid expenses during the period/year are as follows:

	For the six-month period ended 30.6.2022 VND	For the year ended 31.12.2021 VND
Beginning of period/year	38,085,883,030	37,050,980,751
Increase	3,905,599,598	20,929,614,101
Allocation	(10,472,492,591)	(19,894,711,822)
End of period/year	<u>31,518,990,037</u>	<u>38,085,883,030</u>

14 SHORT-TERM TRADE ACCOUNTS PAYABLE

	30.6.2022		31.12.2021	
	Value VND	Able-to-pay amount VND	Value VND	Able-to-pay amount VND
Third parties (*)	58,919,302,592	58,919,302,592	89,689,373,999	89,689,373,999
Related parties (Note 37(b))	2,677,963,598	2,677,963,598	3,023,413,660	3,023,413,660
	<u>61,597,266,190</u>	<u>61,597,266,190</u>	<u>92,712,787,659</u>	<u>92,712,787,659</u>

(*) Details of suppliers accounting for 10% or more of the total balance of short-term trade accounts payable are as follows:

	30.6.2022 VND	31.12.2021 VND
Novartis (Singapore) Pte., Ltd.	16,124,471,670	10,028,253,600
Lupin Limited	6,733,440,000	-
APC Pharmaceuticals Chemical Ltd.	-	24,078,746,242

As at 30 June 2022 and 31 December 2021, there was no balance of short-term trade accounts payable that was past due.

15 SHORT-TERM ADVANCES FROM CUSTOMERS

	30.6.2022 VND	31.12.2021 VND
Third parties (*)	<u>24,599,575,564</u>	<u>25,374,390,853</u>

(*) Details of customers accounting for 10% or more of the total balance of short-term advances from customers are as follows:

	30.6.2022 VND	31.12.2021 VND
Orgalife Nutritional Science Co., Ltd.	7,080,400,000	7,080,400,000
Moc Tinh Pharmaceutical Joint Stock Company	6,877,256,662	5,031,881,552
Newzilan Trading Joint Stock Company	4,000,000,000	7,000,000,000
Nhan Sinh Pharmaceuticals Co., Ltd.	<u>3,361,000,000</u>	<u>1,830,000,000</u>

16 TAX AND OTHER RECEIVABLES FROM/PAYABLES TO THE STATE

Movements in tax and other receivables from/payables to the State during the period are as follows:

	As at 1.1.2022 VND	Payable/ receivable during the period VND	Payment/net off during the period VND	As at 30.6.2022 VND
a) Tax receivable				
VAT to be reclaimed	<u>2,321,523,770</u>	<u>58,687,914,390</u>	<u>(58,718,549,239)</u>	<u>2,290,888,921</u>
b) Tax payables				
BIT - current	17,141,375,774	26,029,283,306	(30,526,027,664)	12,644,631,416
VAT for import	62,471,252	3,611,941,900	(3,674,413,152)	-
Import tax	-	1,032,863,799	(1,032,863,799)	-
Foreign contractor tax	7,535,649	2,980,235,934	(1,832,778,295)	1,154,993,288
Personal income tax for employees	-	7,043,939,982	(7,043,939,982)	-
Other personal income tax	544,379,450	2,358,436,410	(1,498,129,544)	1,404,686,316
VAT output	1,861,099,515	14,363,800,761	(11,829,147,674)	4,395,752,602
Others	-	515,468,076	(515,468,076)	-
	<u>19,616,861,640</u>	<u>57,935,970,168</u>	<u>(57,952,768,186)</u>	<u>19,600,063,622</u>

17 SHORT-TERM ACCRUED EXPENSES

	30.6.2022 VND	31.12.2021 VND
Advertising and promotion	38,887,770,838	33,703,956,346
Maintenance and market development	3,175,064,401	4,342,895,431
Royalty fees	692,096,084	2,983,886,113
	<u>42,754,931,323</u>	<u>41,030,737,890</u>

18 SHORT-TERM UNEARNED REVENUE

The balance represents the unearned revenue corresponding to the value of goods and services provided to customers for free or at discount under customer loyalty programs, for which the Company has not settled the obligations at the end of the period.

19 OTHER SHORT-TERM PAYABLES

	30.6.2022 VND	31.12.2021 VND
Remunerations for the Board of Directors and Board of Supervision	2,177,974,527	3,390,000,905
Union fees	718,876,816	1,045,148,494
Short-term deposits from other enterprises	-	359,545,850
Other payables	47,000,000	-
	<u>2,943,851,343</u>	<u>4,794,695,249</u>

IMEXPHARM CORPORATION

Form B 09a – DN

20 BORROWINGS

(a) Short-term borrowings

	As at 1.1.2022 VND	Increase VND	Current portion VND	Decrease VND	Revaluation VND	As at 30.6.2022 VND
Shinhan Bank Vietnam Limited (i)	80,490,789,243	22,373,528,572	-	(102,864,317,815)	-	-
Asian Development Bank (ii)	91,652,000,000	-	91,652,000,000	(91,652,000,000)	1,948,000,000	93,600,000,000
	<u>172,142,789,243</u>	<u>22,373,528,572</u>	<u>91,652,000,000</u>	<u>(194,516,317,815)</u>	<u>1,948,000,000</u>	<u>93,600,000,000</u>

(b) Long-term borrowing

	As at 1.1.2022 VND	Current portion VND	As at 30.6.2022 VND
Asian Development Bank (ii)	91,652,000,000	(91,652,000,000)	-

- (i) Representing a short-term loan according to the credit facility with a credit limit of VND150 billion. This loan is unsecured and bears interest rate issued in each credit facility. The credit term for each draw-down does not exceed 6 months from the disbursement date for the purpose of financing the Company's working capital requirements.
- (ii) Representing a long-term loan according to the credit facility with a credit limit of USD8 million. This loan is secured by a tangible fixed asset (Note 11(a)) and machinery and equipment in progress (Note 12) which bears interest rate issued in each credit facility, for the purpose of financing the Company's projects. This loan will be repaid a half on the 12th month since the first disbursement date and the rest on the last due date.

21 BONUS AND WELFARE FUND

Movements of bonus and welfare fund during the period/year are as follows:

	For the six-month period ended 30.6.2022 VND	For the year ended 31.12.2021 VND
Beginning of period/year	16,792,243,373	13,538,180,482
Appropriated (Note 23)	23,496,132,787	25,163,625,395
Utilised	(9,946,982,366)	(21,909,562,504)
End of period/year	<u>30,341,393,794</u>	<u>16,792,243,373</u>

22 OWNERS' CAPITAL**(a) Number of shares**

	30.6.2022		31.12.2021	
	Ordinary shares	Preference shares	Ordinary shares	Preference shares
Number of shares registered	<u>66,705,370</u>	<u>-</u>	<u>66,705,370</u>	<u>-</u>
Number of shares issued	66,705,370	-	66,705,370	-
Number of shares repurchased	(33,800)	-	(33,800)	-
Number of existing shares in circulation	<u>66,671,570</u>	<u>-</u>	<u>66,671,570</u>	<u>-</u>

(b) Details of owners' shareholding

	30.6.2022		31.12.2021	
	Ordinary shares	%	Ordinary shares	%
SK Investment Vina III Pte. Ltd.	31,066,190	46.57	19,621,743	29.42
Vietnam Pharmaceutical Corporation	14,696,534	22.03	14,696,534	22.03
Kwe Beteiligungen AG	-	-	10,112,023	15.16
Sunrise Kim Investment Joint Stock Company	6,466,039	9.69	6,199,039	9.29
KBA Investment Joint Stock Company	4,915,726	7.37	4,915,726	7.37
Shareholding owned by other owners	9,560,881	14.34	11,160,305	16.73
	<u>66,705,370</u>	<u>100.00</u>	<u>66,705,370</u>	<u>100.00</u>

22 OWNERS' CAPITAL (continued)

(c) Movements of share capital

	Number of shares	Ordinary shares VND	Total VND
As at 1 January 2021, 31 December 2021 and 30 June 2022	66,705,370	667,053,700,000	667,053,700,000

Par value per share: VND10,000.

IMEXPHARM CORPORATION

Form B 09a – DN

23 MOVEMENTS IN OWNERS' EQUITY

	Owners' capital VND	Share premium VND	Owners' other capital VND	Treasury shares VND	Investment and development fund VND	Post-tax undistributed earnings VND	Total VND
As at 1 January 2021	667,053,700,000	507,368,247,904	2,420,789,142	(358,600,000)	348,765,273,377	205,236,758,013	1,730,486,168,436
Net profit for the year	-	-	-	-	-	189,094,874,963	189,094,874,963
Cash dividend declared	-	-	-	-	-	(100,007,355,000)	(100,007,355,000)
Appropriation to Investment and development fund	-	-	-	-	79,650,870,265	(79,650,870,265)	-
Appropriation to Bonus and welfare fund	-	-	-	-	-	(25,163,625,395)	(25,163,625,395)
Fund utilisation	-	-	-	-	(7,914,593,222)	7,914,593,222	-
As at 31 December 2021	667,053,700,000	507,368,247,904	2,420,789,142	(358,600,000)	420,501,550,420	197,424,375,538	1,794,410,063,004
Net profit for the period	-	-	-	-	-	99,213,424,181	99,213,424,181
Cash dividend declared (*) (Note 24)	-	-	-	-	-	(100,007,355,000)	(100,007,355,000)
Appropriation to Investment and development fund (*)	-	-	-	-	72,297,618,771	(72,297,618,771)	-
Appropriation to Bonus and welfare fund (*) (Note 21)	-	-	-	-	-	(23,496,132,787)	(23,496,132,787)
Fund utilisation	-	-	-	-	(8,560,694,359)	8,560,694,359	-
As at 30 June 2022	667,053,700,000	507,368,247,904	2,420,789,142	(358,600,000)	484,238,474,832	109,397,387,520	1,770,119,999,398

23 MOVEMENTS IN OWNERS' EQUITY (continued)

(*) In accordance with Resolution No. 02/NQ-ĐHĐCĐ-IMP of the Annual General Meeting of Shareholders of the Company on 25 April 2022, the Annual General Meeting of Shareholders has approved the 2021 profit after tax distribution plan as follows:

- a) Dividend payment at the rate of 15% of the par value of shares in circulation in form of cash of VND100,007,355,000. In accordance with Article 1, Resolution No. 10/NQ-ĐHCĐ-IMEX of the Company's Board of Management on 4 May 2022, the Board of Management has approved the last registration date as 26 May 2022 and the date of dividend payment in form of cash as 24 June 2022. At the date of these interim financial statements, the Company completed their cash dividend payment to their shareholders;
- b) Appropriation to investment and development fund at the rate of 36.92% from post-tax undistributed earnings as VND72,297,618,771; and
- c) Appropriation to bonus and welfare fund at the rate of 12% from post-tax undistributed earnings as VND23,496,132,787.

24 DIVIDENDS PAYABLE

Movements of dividends payable during the period/year are as follows:

	For the six-month period ended 30.6.2022 VND	For the year ended 31.12.2021 VND
Beginning of period/year	-	-
Dividends payable during the period/year (Note 23)	100,007,355,000	100,007,355,000
Dividends paid in cash	(100,007,355,000)	(100,007,355,000)
End of period/year	-	-

25 EARNINGS PER SHARE**(a) Basic earnings per share**

Basic earnings per share is calculated by dividing the net profit attributable to shareholders after deducting the bonus and welfare fund by the weighted average number of ordinary shares outstanding during the period, excluding ordinary shares repurchased by the Company and held as treasury shares. Details are as follows:

	For the six-month period ended	
	30.6.2022	30.6.2021
Net profit attributable to shareholders (VND)	99,213,424,181	91,179,995,836
Add tax arrears compensated by investment and development fund (VND)	-	4,741,710,650
Less amount allocated to bonus and welfare fund (VND) (*)	(11,905,610,902)	(11,510,604,778)
	<u>87,307,813,279</u>	<u>84,411,101,708</u>
Weighted average number of ordinary shares in issue (shares)	66,671,570	66,671,570
Basic earnings per share (VND)	<u>1,310</u>	<u>1,266</u>

(*) The amount allocated to bonus and welfare fund for the six-month period ended 30 June 2022 was estimated based on the appropriation rate for bonus and welfare fund from post-tax undistributed earnings in accordance with the 2021 profit distribution scheme which was approved at the Annual General Meeting of Shareholders of the Company.

(b) Diluted earnings per share

The Company did not have potential shares which diluted earnings per shares.

26 OFF BALANCE SHEET ITEMS**(a) Foreign currencies**

	30.6.2022	31.12.2021
United States Dollar ("USD")	25,900.02	35,210.17
Euro ("EUR")	<u>13,915.70</u>	<u>13,915.70</u>

(b) Bad debts written off

	30.6.2022	31.12.2021
	VND	VND
Bad debts written off	<u>32,945,346,171</u>	<u>24,122,380,526</u>

27 NET REVENUE FROM SALES OF GOODS

	For the six-month period ended	
	30.6.2022	30.6.2021
	VND	VND
Revenue		
Sales of finished goods	655,694,770,882	594,907,409,862
Sale of franchised goods	9,920,119,968	22,438,700,000
Sales of others	6,187,260,371	5,489,104,894
	<u>671,802,151,221</u>	<u>622,835,214,756</u>
Sales deductions		
Trade discounts	(2,831,466,700)	(7,094,507,424)
Sales returns	(176,888,872)	(1,455,502,910)
Sales rebates	(97,040,000)	(423,980,800)
	<u>(3,105,395,572)</u>	<u>(8,973,991,134)</u>
Net revenue from sales of goods	<u>668,696,755,649</u>	<u>613,861,223,622</u>

28 COST OF GOODS SOLD

	For the six-month period ended	
	30.6.2022	30.6.2021
	VND	VND
Cost of finished goods sold	325,225,455,904	292,854,367,934
Cost of promotion goods	45,259,150,857	39,885,609,092
Cost of franchised goods	7,467,811,818	16,624,210,333
Cost of others	4,825,509,693	5,341,290,915
Provision/(reversal of provision) for decline in value of inventories (Note 10)	2,189,164,584	(1,483,225,218)
	<u>384,967,092,856</u>	<u>353,222,253,056</u>

29 FINANCIAL INCOME

	For the six-month period ended	
	30.6.2022	30.6.2021
	VND	VND
Dividend income	5,974,126,000	242,584,000
Interest income from deposits and lending	5,777,817,160	3,187,473,900
Realised foreign exchange gains	1,786,159,238	1,066,160,604
Net gain from foreign currency translation at period-end	-	62,249,701
	<u>13,538,102,398</u>	<u>4,558,468,205</u>

30 FINANCIAL EXPENSES

	For the six-month period ended	
	30.6.2022 VND	30.6.2021 VND
Payment discounts	9,331,866,421	5,960,570,061
Net loss from foreign currency translation at period-end	2,279,366,772	-
Interest expense	2,192,395,206	2,706,399,236
Realised foreign exchange losses	229,525,901	163,899,000
Reversal of provision for diminution in value of investments	(377,057,144)	(84,148,650)
Others	40,049,444	1,171,143,442
	<u>13,696,146,600</u>	<u>9,917,863,089</u>

31 SELLING EXPENSES

	For the six-month period ended	
	30.6.2022 VND	30.6.2021 VND
Staff costs	52,080,576,603	44,585,735,319
Raw materials	21,204,515,945	15,853,347,130
Conference and business travel	16,796,067,351	17,852,128,906
Marketing, maintenance, and market development	13,950,317,778	18,615,473,861
Outside services	4,066,284,219	4,741,934,396
Depreciation and amortisation	2,791,503,186	3,003,971,169
Repairs and maintenance	542,802,733	924,534,838
Other expenses	3,481,461,694	3,508,490,157
	<u>114,913,529,509</u>	<u>109,085,615,776</u>

32 GENERAL AND ADMINISTRATION EXPENSES

	For the six-month period ended	
	30.6.2022 VND	30.6.2021 VND
Staff costs	12,423,771,303	11,985,387,825
Outside services	5,953,803,062	4,939,962,390
Remunerations for the Board of Directors and Board of Supervision	2,555,973,622	2,386,650,710
Depreciation and amortisation	2,289,421,548	2,132,435,193
Conference and business travel	1,278,391,841	1,121,969,003
Other expenses	19,390,990,418	10,929,238,444
	<u>43,892,351,794</u>	<u>33,495,643,565</u>

33 CORPORATE INCOME TAX

The corporate income tax on the Company's profit before tax differs from the theoretical amount that would arise using the applicable tax rate of 20% as follows:

	For the six-month period ended	
	30.6.2022	30.6.2021
	VND	VND
Net accounting profit before tax	125,242,707,487	116,945,884,814
Tax calculated at a rate of 20%	25,048,541,497	23,389,176,963
Effect of:		
Income not subject to tax	(1,194,825,200)	(48,516,800)
Expenses not deductible for tax purposes	739,297,712	983,428,344
Temporary difference for which no deferred income tax asset was recognised	1,712,138,872	-
(Over-provision)/under-provision in previous years	(275,869,575)	1,441,800,471
Corporate income tax charge (*)	26,029,283,306	25,765,888,978
Charged to income statement:		
Corporate income tax – current	26,029,283,306	25,765,888,978
Corporate income tax – deferred	-	-
	26,029,283,306	25,765,888,978

(*) The corporate income tax charge for the period is based on estimated taxable income and is subject to review and possible adjustments by the tax authorities.

34 COST OF OPERATION BY FACTORS

	For the six-month period ended	
	30.6.2022	30.6.2021
	VND	VND
Raw materials	235,200,273,933	232,697,401,093
Staff costs	121,552,648,281	111,065,251,763
Outside services	48,269,757,677	47,381,541,199
Depreciation and amortisation	30,176,403,086	29,769,091,890
Others	112,636,945,176	98,577,179,988
	547,836,028,153	519,490,465,933

35 BUSINESS AND GEOGRAPHICAL SEGMENTS*Geographical segment*

The Company's revenue is mainly generated by domestic sales whereas export sales only account for a small portion in the total revenue in the Company's interim income statement for the period from 1 January 2022 to 30 June 2022 and the comparative periods. Therefore, the Company did not present geographical segment.

Business segment

The Company's principal activities are to manufacture pharmaceutical products and trade materials used for processing pharmaceutical products. Other business activities only make up a small portion in the total revenue. Therefore, the Company did not present business segment.

36 ADDITIONAL INFORMATION FOR THE ITEMS OF THE INTERIM STATEMENT OF CASH FLOWS

Non-cash transactions affect the interim statement of cash flows

	For the six-month period ended	
	30.6.2022 VND	30.6.2021 VND
Purchases of fixed assets not yet paid	6,160,182,795	8,996,226,810

37 RELATED PARTY DISCLOSURES**(a) Related party transactions**

During the period, the following major transactions were carried out with related parties:

	For the six-month period ended	
	30.6.2022 VND	30.6.2021 VND
i) Sales of goods		
Associate		
Agimexpharm Pharmaceutical Joint Stock Company	5,661,971,040	1,084,099,314
ii) Purchases of goods		
Associate		
Agimexpharm Pharmaceutical Joint Stock Company	10,029,522,820	4,846,740,150

37 RELATED PARTY DISCLOSURES (continued)

(a) Related party transactions (continued)

	For the six-month period ended	
	30.6.2022	30.6.2021
	VND	VND
iii) <i>Sales of fixed assets</i>		
Associate		
Agimexpharm Pharmaceutical		
Joint Stock Company	-	1,182,727,272

IMEXPHARM CORPORATION

Form B 09a – DN

37 RELATED PARTY DISCLOSURES (continued)

(a) Related party transactions (continued)

		For the six-month period ended	
		30.6.2022	30.6.2021
		VND	VND
iv) Compensation of key management			
Net salary after tax			
Mrs. Tran Thi Dao	Vice Chairwoman of Board of Directors cum General Director	1,545,723,397	1,498,843,094
Mr. Nguyen Quoc Dinh	Chairman of Board of Directors cum Deputy General Director	647,900,435	914,454,892
Mr. Ngo Minh Tuan	Member of Board of Directors cum Deputy General Director	522,777,180	682,475,002
Mr. Le Van Nha Phuong	Member of Board of Directors cum Deputy General Director	802,707,273	884,716,854
Mr. Huynh Van Nhung	Deputy General Director	897,192,492	823,666,397
Mr. Tran Hoai Hanh	Chief Accountant	393,083,999	516,103,139
Remuneration and bonuses after tax			
Mr. Nguyen Quoc Dinh	Chairman of Board of Directors cum Deputy General Director	1,000,000,000	888,000,000
Mrs. Tran Thi Dao	Vice Chairwoman of Board of Directors cum General Director	600,000,000	560,000,000
Mr. Ngo Minh Tuan	Member of Board of Directors cum Deputy General Director	300,000,000	276,000,000
Mr. Le Van Nha Phuong	Member of Board of Directors cum Deputy General Director	300,000,000	266,400,000
Mrs. Han Thi Khanh Vinh	Member of Board of Directors	229,500,000	193,500,000
Mr. Tran Anh Tuan	Member of Board of Directors	232,500,000	193,500,000
Mr. Truong Minh Hung	Member of Board of Directors	229,500,000	190,100,000
Mr. Nguyen Duc Tuan	Chief Supervisor	211,500,000	227,500,000
Mrs. Le Thi Kim Chung	Chief Supervisor	170,000,000	159,600,000
Mrs. Do Thi Thanh Thuy	Member of Board of Supervision	113,400,000	153,600,000
Mrs. Nguyen Thi Kim Le	Secretary of Board of Directors	155,000,000	159,600,000
Total		8,350,784,776	8,588,059,378

37 RELATED PARTY DISCLOSURES (continued)

(a) Related party transactions (continued)

	For the six-month period ended	
	30.6.2022 VND	30.6.2021 VND
v) Financing activities	-	-
Associate		
Dividend distribution to Agimexpharm Pharmaceutical Joint Stock Company	22,185,000	22,185,000
Additional investments to Agimexpharm Pharmaceutical Joint Stock Company	20,327,136,000	-
Dividend received from Agimexpharm Pharmaceutical Joint Stock Company	5,928,748,000	-

(b) Period/year end balances with related parties

	30.6.2022 VND	31.12.2021 VND
i) Short-term trade accounts receivable (Note 5)		
Associate		
Agimexpharm Pharmaceutical Joint Stock Company	5,762,999,377	2,295,913,712
ii) Short-term trade accounts payable (Note 14)		
Associate		
Agimexpharm Pharmaceutical Joint Stock Company	2,677,963,598	3,023,413,660

38 CAPITAL EXPENDITURE COMMITMENTS

Capital expenditure contracted for at the balance sheet date but not recognised in the financial statements was as follows:

	30.6.2022 VND	31.12.2021 VND
Property, plants and equipment	<u>37,672,365,884</u>	<u>45,663,803,930</u>

The interim financial statements were approved by the Board of Management on 9 August 2022.



Duong Hoang Vu
Preparer



Tran Hoai Hanh
Chief Accountant




Nguyen Quoc Dinh
Deputy General Director
Authorised by Legal
Representative